NEW YORK (GenomeWeb) – Myriad Genetics today announced a companion diagnostic development pact with BeiGene, a company developing cancer treatments combining immunotherapy and molecularly targeted drugs.
NEW YORK (GenomeWeb) – Myriad Genetics today announced a companion diagnostic development pact with BeiGene, a company developing cancer treatments combining immunotherapy and molecularly targeted drugs.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.